Goserelin

In plain language

Goserelin is a monthly or three-monthly implant injected under the skin of the abdomen, sold as Zoladex. It is used for prostate cancer, some breast cancers, and certain benign gynecological conditions.

It works by flooding the brain's control switch for sex hormones. At first hormone levels rise, then the switch exhausts and testosterone in men or estrogen in women falls to near zero, which starves hormone-dependent tumors. Side effects are like a sudden menopause or andropause: hot flashes, bone thinning, and loss of libido.

For students

Goserelin is a synthetic GnRH decapeptide analogue (about 1,266 Da) with D-Ser(tBu) at position 6 and aza-glycine at position 10, substitutions that increase receptor affinity and resist enzymatic degradation. Sustained receptor occupancy produces the paradox seen with all GnRH agonists: an initial LH/FSH surge, then pituitary receptor desensitization with castrate-level sex hormones within 2-4 weeks.

The biodegradable implant (a 1 mm cylinder injected with a specially designed syringe) releases drug steadily over 28 or 84 days, which eliminates the compliance problem of daily injections. It is used for advanced prostate cancer, node-positive breast cancer in ER-positive disease, endometriosis and uterine fibroids. A bone mineral density and metabolic syndrome profile accompanies long-term androgen-deprivation use.

For researchers and instructors

Biochemistry. The position 6 D-amino acid and position 10 aza-glycine replacement are the two classic stabilizing modifications shared across first-generation GnRH agonists, first commercialized in leuprolide and goserelin.

Pharmacology. Depot duration (1 or 3 months) is set by the polymer matrix; testosterone suppression to castrate levels is equivalent to surgical orchiectomy in metastatic prostate cancer, a result established in the 1980s-90s.

Human evidence. Randomized comparisons against orchiectomy and diethylstilbestrol in prostate cancer established equivalence with a better safety profile; breast cancer data came from pivotal trials in ER-positive advanced disease.

Teaching point. The archetypal example of receptor downregulation as a therapeutic strategy: overstimulating a pathway to shut it down.